While the authors showed that receipt of aromatase inhibitors, and zoledronic acid were significant predictors of survival in patients with de novo metastatic disease, it was less clear whether these treatment contributed towards the improved survival trend5. This evidence concerns the gene CYP19A1 and metastatic neoplasm.